Lantheus enters into collaboration with CarThera for use of microbubbles
Lantheus Holdings announced it has entered into a strategic commercial supply agreement with CarThera for the use of Lantheus' microbubbles in combination with SonoCloud, a proprietary implantable device in development for the treatment of recurrent glioblastoma. Under the commercial supply agreement, Lantheus' microbubbles will be used as a component in CarThera's SonoCloud System, which uses low-intensity pulsed ultrasound specifically designed to open the blood-brain barrier to facilitate more effective delivery of chemotherapy to tumors. As part of the agreement, CarThera will be responsible for regulatory filings and approvals in the U.S., Europe and rest of world as well as commercialization of SonoCloud. Lantheus will supply its microbubble vials and activation devices at a predetermined transfer price. Additionally, Lantheus will receive royalties on the SonoCloud kit product sales upon regulatory approval.